Capricor Therapeutics
CAPR
19 hedge funds and large institutions have $3.01M invested in Capricor Therapeutics in 2017 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 4 closing their positions.
377% more capital invested
Capital invested by funds: $630K → $3.01M (+$2.38M)
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
6% more funds holding
Funds holding: 18 → 19 (+1)
0.09% more ownership
Funds ownership: 0.34% → 0.42% (+0.09%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$429K |
| 2 |
Jane Street
New York
|
+$75.2K |
| 3 |
Wells Fargo
San Francisco,
California
|
+$42.3K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$30.6K |
| 5 |
CFN
Cordasco Financial Network
Naples,
Florida
|
+$3.71K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CBA
Coastal Bridge Advisors
Westport,
Connecticut
|
-$77.8K |
| 2 |
Goldman Sachs
New York
|
-$34K |
| 3 |
Morgan Stanley
New York
|
-$20K |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
-$20K |
| 5 |
SEI Investments
Oaks,
Pennsylvania
|
-$1K |
CAPR Hedge Fund Activity: Q3 2017 in Review
19 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Capricor Therapeutics (CAPR) for Q3 2017, worth a combined $3.01M — up 377% from $630K a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new CAPR positions and 4 closed out — a net gain of 2 holders — while 3 added to existing stakes and 1 trimmed.
The largest buyer was Vanguard Group, adding an estimated $429K. The largest seller was Coastal Bridge Advisors, cutting an estimated $77.8K.
- 19 institutional investors held Capricor Therapeutics (CAPR) as of Q3 2017, up from 18 in Q2 2017.
- Funds reported $3.01M of Capricor Therapeutics stock for Q3 2017, up 377% quarter-over-quarter.
- 6 funds opened new Capricor Therapeutics positions in Q3 2017 and 4 closed out, a net change of +2 holders.
- The largest Capricor Therapeutics buyer in Q3 2017 was Vanguard Group, an estimated $429K added.
- The largest Capricor Therapeutics seller in Q3 2017 was Coastal Bridge Advisors, an estimated $77.8K sold.
Based on aggregated 13F filings for Q3 2017.